Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 293

1.

Regional nodal metastatic disease is the strongest predictor of survival in patients with thin vertical growth phase melanomas: a case for SLN Staging biopsy in these patients.

Karakousis GC, Gimotty PA, Czerniecki BJ, Elder DE, Elenitsas R, Ming ME, Fraker DL, Guerry D, Spitz FR.

Ann Surg Oncol. 2007 May;14(5):1596-603. Epub 2007 Feb 7.

PMID:
17285396
2.

Predictors of regional nodal disease in patients with thin melanomas.

Karakousis GC, Gimotty PA, Botbyl JD, Kesmodel SB, Elder DE, Elenitsas R, Ming ME, Guerry D, Fraker DL, Czerniecki BJ, Spitz FR.

Ann Surg Oncol. 2006 Apr;13(4):533-41. Epub 2006 Mar 7.

PMID:
16523360
3.

Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas.

Cherpelis BS, Haddad F, Messina J, Cantor AB, Fitzmorris K, Reintgen DS, Fenske NA, Glass LF.

J Am Acad Dermatol. 2001 May;44(5):762-6.

PMID:
11312421
4.

Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database.

Mandalà M, Imberti GL, Piazzalunga D, Belfiglio M, Labianca R, Barberis M, Marchesi L, Poletti P, Bonomi L, Novellino L, Di Biagio K, Milesi A, Guerra U, Tondini C.

Eur J Cancer. 2009 Sep;45(14):2537-45. doi: 10.1016/j.ejca.2009.05.034. Epub 2009 Jun 22.

PMID:
19553103
5.

Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (> or = 4 mm) primary melanoma.

Gershenwald JE, Mansfield PF, Lee JE, Ross MI.

Ann Surg Oncol. 2000 Mar;7(2):160-5.

PMID:
10761797
6.

Survival analysis and clinicopathological factors associated with false-negative sentinel lymph node biopsy findings in patients with cutaneous melanoma.

Nowecki ZI, Rutkowski P, Nasierowska-Guttmejer A, Ruka W.

Ann Surg Oncol. 2006 Dec;13(12):1655-63. Epub 2006 Oct 3.

PMID:
17016755
7.

Sentinel lymph node biopsy in melanoma: a micromorphometric study relating to prognosis and completion lymph node dissection.

Debarbieux S, Duru G, Dalle S, Béatrix O, Balme B, Thomas L.

Br J Dermatol. 2007 Jul;157(1):58-67. Epub 2007 May 14.

PMID:
17501957
8.

Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas.

Kesmodel SB, Karakousis GC, Botbyl JD, Canter RJ, Lewis RT, Wahl PM, Terhune KP, Alavi A, Elder DE, Ming ME, Guerry D, Gimotty PA, Fraker DL, Czerniecki BJ, Spitz FR.

Ann Surg Oncol. 2005 Jun;12(6):449-58. Epub 2005 Apr 19.

PMID:
15864482
9.

Patterns of recurrence after sentinel lymph node biopsy for cutaneous melanoma.

Fincher TR, McCarty TM, Fisher TL, Preskitt JT, Lieberman ZH, Stephens JF, O'Brien JC, Kuhn JA.

Am J Surg. 2003 Dec;186(6):675-81.

PMID:
14672778
10.

Should all patients with melanoma between 1 and 2 mm Breslow thickness undergo sentinel lymph node biopsy?

Mays MP, Martin RC, Burton A, Ginter B, Edwards MJ, Reintgen DS, Ross MI, Urist MM, Stromberg AJ, McMasters KM, Scoggins CR.

Cancer. 2010 Mar 15;116(6):1535-44. doi: 10.1002/cncr.24895.

11.

Sentinel lymph node biopsy in patients with thin primary cutaneous melanoma.

Murali R, Haydu LE, Quinn MJ, Saw RP, Shannon K, Spillane AJ, Stretch JR, Thompson JF, Scolyer RA.

Ann Surg. 2012 Jan;255(1):128-33. doi: 10.1097/SLA.0b013e3182306c72.

PMID:
21975320
12.

Role of sentinel lymph node biopsy in patients with thin melanoma.

Andtbacka RH, Gershenwald JE.

J Natl Compr Canc Netw. 2009 Mar;7(3):308-17. Review.

PMID:
19401063
13.

Prognostic significance of a positive nonsentinel lymph node in cutaneous melanoma.

Ghaferi AA, Wong SL, Johnson TM, Lowe L, Chang AE, Cimmino VM, Bradford CR, Rees RS, Sabel MS.

Ann Surg Oncol. 2009 Nov;16(11):2978-84. doi: 10.1245/s10434-009-0665-4. Epub 2009 Aug 27.

PMID:
19711133
14.

Predicting sentinel node status in AJCC stage I/II primary cutaneous melanoma.

Kruper LL, Spitz FR, Czerniecki BJ, Fraker DL, Blackwood-Chirchir A, Ming ME, Elder DE, Elenitsas R, Guerry D, Gimotty PA.

Cancer. 2006 Nov 15;107(10):2436-45.

15.

Sentinel lymph node biopsy for cutaneous melanoma: the Stanford experience, 1997-2004.

Berk DR, Johnson DL, Uzieblo A, Kiernan M, Swetter SM.

Arch Dermatol. 2005 Aug;141(8):1016-22.

PMID:
16103331
16.

Lymphatic invasion identified by monoclonal antibody D2-40, younger age, and ulceration: predictors of sentinel lymph node involvement in primary cutaneous melanoma.

Niakosari F, Kahn HJ, McCready D, Ghazarian D, Rotstein LE, Marks A, Kiss A, From L.

Arch Dermatol. 2008 Apr;144(4):462-7. doi: 10.1001/archderm.144.4.462.

PMID:
18427039
17.

Sentinel lymph node status is the most important prognostic factor for thick (> or = 4 mm) melanomas.

Gutzmer R, Satzger I, Thoms KM, Völker B, Mitteldorf C, Kapp A, Bertsch HP, Kretschmer L.

J Dtsch Dermatol Ges. 2008 Mar;6(3):198-203. Epub 2007 Dec 17. English, German.

PMID:
18093216
18.

American Joint Committee on Cancer clinical stage as a selection criterion for sentinel lymph node biopsy in thin melanoma.

Vaquerano J, Kraybill WG, Driscoll DL, Cheney R, Kane JM 3rd.

Ann Surg Oncol. 2006 Feb;13(2):198-204. Epub 2006 Jan 19.

PMID:
16418885
19.

Sentinel node status in melanoma patients is not predictive for overall survival upon multivariate analysis.

Roka F, Kittler H, Cauzig P, Hoeller C, Hinterhuber G, Wolff K, Pehamberger H, Diem E.

Br J Cancer. 2005 Feb 28;92(4):662-7.

20.

Multivariate prognostic model for patients with thick cutaneous melanoma: importance of sentinel lymph node status.

Ferrone CR, Panageas KS, Busam K, Brady MS, Coit DG.

Ann Surg Oncol. 2002 Aug;9(7):637-45.

PMID:
12167577

Supplemental Content

Support Center